Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Colorectal Neoplasms 3Sarcoma 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × conatumumab × Clear all
NCT00819169 2024-08-20

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NantCell, Inc.

Phase 1/2 Terminated
89 enrolled 20 charts
GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00626704 2015-05-25

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Amgen

Phase 1/2 Completed
134 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡